You have 9 free searches left this month | for more free features.

hl-085

Showing 1 - 9 of 9

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Melanoma Trial in Beijing (HL-085, Vemurafenib)

Recruiting
  • Melanoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 10, 2022

Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)

Recruiting
  • Neurofibromatosis 1
  • Plexiform Neurofibromas
  • HL-085
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital, Shanghai JiaoTong University S
Apr 10, 2022

Melanoma Trial in Beijing (HL-085)

Recruiting
  • Melanoma
  • HL-085
  • Beijing, Beijing, China
  • +1 more
Jan 19, 2022

CRC Trial in Beijing (HL-085, Vemurafenib)

Not yet recruiting
  • CRC
  • Beijing, Beijing, China
    Beijing Oncology Hospital
Feb 6, 2022

Nsclc Trial in Beijing (HL-085, Docetaxel)

Terminated
  • Nsclc
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Science
Nov 29, 2021

Melanoma Trial in Beijing, Shanghai (HL-085)

Recruiting
  • Melanoma
  • HL-085
  • Beijing, Beijing, China
  • +1 more
Dec 16, 2021

Solid Tumor Trial in Beijing, Zhengzhou, Hangzhou (HL-085, Vemurafenib)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
  • +3 more
Jan 20, 2022

Solid Tumor, Adult Trial in United States (HL-085)

Recruiting
  • Solid Tumor, Adult
  • HL-085
  • San Marcos, California
  • +4 more
Mar 17, 2021

Solid Tumor, Adult Trial in Austin, San Antonio (HL-085)

Terminated
  • Solid Tumor, Adult
  • HL-085
  • Austin, Texas
  • +1 more
Nov 16, 2020